Table 1.

Characteristics of the seven included studies.

Study	Study design	No. of participant (total/data extraction)	Mean age (range)	Triage	Specimen type	Index test	Comparator	Detection	Reference standard
Ordi et al18	Prospective, consecutive	1169/1123	35.8 (18–91)	abnormal Pap test	ThinPrep	CINtec PLUS	Hybrid Capture 2	CIN2+	Biopsy, endocervical curettage
Killeen et al19	Prospective, consecutive	515/232	35.8 (21–86)	ASCUS, LSIL, ASC-H, HSIL	ThinPrep	CINtec PLUS	Cervista	CIN2/3	Biopsy
Vrdoljak-Mozetic et al20	Prospective	155/145	34.9 (19–69)	CIN1	Conventional smear	CINtec PLUS	Hybrid Capture 2	CIN2+	Biopsy
Byun et al21	Prospective	56/56	46 (25–83)	ASC-H, LSIL-H	SurePath	CINtec PLUS	Cytoactive	CIN2+	Histology
Waldstroem et al22	Consecutive	469/469	32.3 (16–25)	LSIL	ThinPrep	CINtec PLUS	APTIMA	CIN2+/CIN3+	Histology
Loghavi et al23	Retrospective	188/188	median: 30 (15–77)	ASCUS, LSIL	SurePath	CINtec PLUS	Cervista	CIN2+	Histology
Schmidt et al24	Retrospective, consecutive	810/415	>18	LSIL	ThinPrep	CINtec PLUS	Hybrid Capture 2	CIN2+/CIN3	Biopsy

ASCUS= atypical squamous cells of undetermined significance; ASC-H= atypical squamous cells cannot exclude high grade squamous intraepithelial lesion; CIN= cervical intraepithelial neoplasia; CIN 2+ = cervical intraepithelial neoplasia 2 or worse; CIN 3+ = cervical intraepithelial neoplasia 3 or worse; HSIL= high-grade squamous intraepithelial lesion; LSIL= low-grade squamous intraepithelial lesion; LSIL-H= low-grade squamous intraepithelial lesion cannot exclude high grade squamous intraepithelial lesion. Manufacturers are as follows (listed in alphabetical order by product): APTIMA, Gen-Probe company; Cervista, Hologic; CINtec PLUS, Roche; Cytoactive, Cytoimmun Diagnostics GmbH; Hybrid Capture 2, QIAGEN; SurePath, Becton, Dickinson and Company; ThinPrep, Hologic